Učitavanje...
1ISG-007 Biosimilar of infliximab: does the penetration rate meet expectations? appraisal in a central purchasing office
BACKGROUND: Prescription of biosimilars on a large scale is an important lever to decrease hospital expenses. As a result, 40 M€ of savings are expected in the healthcare bill by the promotion of biosimilar use in 2018. In 2015, one wholesaler (WS) listed one of the two biosimilars of infliximab. PU...
Spremljeno u:
| Izdano u: | Eur J Hosp Pharm |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Group
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535251/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.7 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|